Rhumbline Advisers Provention Bio, Inc. Transaction History

Rhumbline Advisers

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$6.7 - $24.21 $32,186 - $116,304	4,804 Added 5.91%	86,095 $2.08 Million
Q4 2022 Feb 14, 2023	BUY	$4.52 - $10.57 $29,050 - $67,933	6,427 Added 8.58%	81,291 $859,000
Q3 2022 Nov 10, 2022	BUY	$3.43 - $5.62 $27,837 - $45,611	8,116 Added 12.16%	74,864 $337,000
Q2 2022 Aug 11, 2022	SELL	$3.65 - $7.3 $15,293 - $30,587	-4,190 Reduced 5.91%	66,748 $267,000
Q1 2022 May 12, 2022	SELL	$3.4 - $7.88 $22,875 - $53,016	-6,728 Reduced 8.66%	70,938 $519,000
Q4 2021 Feb 10, 2022	BUY	$5.59 - $7.39 $1,962 - $2,593	351 Added 0.45%	77,666 $436,000
Q3 2021 Nov 12, 2021	BUY	$5.66 - $8.33 $7,007 - $10,312	1,238 Added 1.63%	77,315 $495,000
Q2 2021 Aug 05, 2021	BUY	$6.71 - $11.04 $143,177 - $235,571	21,338 Added 38.98%	76,077 $641,000
Q1 2021 May 06, 2021	SELL	$10.12 - $19.45 $10,271 - $19,741	-1,015 Reduced 1.82%	54,739 $574,000
Q4 2020 Feb 10, 2021	BUY	$11.79 - $18.94 $58,560 - $94,074	4,967 Added 9.78%	55,754 $944,000
Q3 2020 Nov 12, 2020	SELL	$10.34 - $15.2 $61,884 - $90,972	-5,985 Reduced 10.54%	50,787 $652,000
Q2 2020 Aug 13, 2020	BUY	$7.81 - $17.0 $443,389 - $965,124	56,772 New	56,772 $801,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.